B. Riley Securities initiated coverage on RadNet with a new price target
$RDNT
Medical Specialities
Health Care
B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | $92.00 | Overweight | KeyBanc Capital Markets |
| 6/13/2025 | $69.00 | Buy | B. Riley Securities |
| 3/5/2025 | $85.00 → $65.00 | Outperform → Strong Buy | Raymond James |
| 9/6/2024 | $57.00 → $79.00 | Equal Weight → Overweight | Barclays |
| 3/6/2024 | $48.00 | Equal Weight | Barclays |
| 8/31/2023 | $40.00 | Buy | Truist |
| 3/31/2023 | $30.00 | Market Outperform | CJS Securities |
| 3/3/2023 | $30.00 | Mkt Perform → Outperform | Raymond James |
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
8-K - RadNet, Inc. (0000790526) (Filer)
KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00
B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00
Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously
SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities: Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducin
LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the "Third Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, as amended by the Third Amendment, the "Credit Agreement"). Pursuant to the Third Amendment, certain term lenders under the Credit Agreement funded RadNet an incremental t
SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians. Reporting Pro was introduced at RSNA 2025 and is now available for commercial deployment. Reporting Pro includes capabilities that bring speech recognition, AI-generated clinical findings, measurements, AI-generated impressions, quality assurance and structured reporting into one seamless workflow. "Radiology is ent
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA(1) decreased to $1.3 million in the first quarter of 2026 from $3.7 million i
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c. An archived replay of the call will also be available
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr
CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog
Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo